Hemophilia Market By Key Manufacturers, By Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Treatment (Replacement Therapy, ITI Therapy, and Gene Therapy) and By Regions (North America, Europe, Middle East and Africa, Latin America and Asia Pacific) - Global Outlook to 2026
Report ID: 134686 | May 2019 | No. of Pages: 120 |
Covid-19 Impact Analysis & Forecast

Global Hemophilia Market is valued USD 10.8 Billion in 2018 and is projected is to exhibit 4.8% CAGR during the forecast period. The market is driven by the rising number of hemophilia cases across the globe and growing genetic disorders.


Hemophilia is a rare disorder in which the blood doesn't clot normally as it lacks sufficient blood-clotting proteins (clotting factors). Patients with hemophilia bleed for a longer time after an injury than a normal person.
Hemophilia Market Dynamics
Growing diagnostic rates backed by rising neonatal population, increasing adoption of prophylaxis treatment, favorable government initiatives, and reimbursements across the globe can be the key factors attributing to the growth of Hemophilia Market in the coming years. However, high costs of treatment and low rates of adoption in developing nations are expected to restraint the market growth to a certain extent in the coming years.


Incessant approvals by regulatory bodies for commercial availability of hemophilia treatment and increasing R&D investments by key manufacturers to develop novel drugs are expected to offer significant growth opportunities in the coming years. Furthermore, awareness programs and initiatives by government, private and NGOs are anticipated to boost the market growth in the coming years.
Hemophilia Market Insight
North America holds the major market share of the global Hemophilia Market due to focus of key market players on strengthening their presence in the US. These companies have been taking up various organic and inorganic growth strategies to enhance its presence in the US. Furthermore, increasing adoption rates for hemophilia treatment and growing awareness on prevention of hemophilia are expected to bolster the market growth during the forecast period.
Hemophilia Market Segmentation
The global Hemophilia Market is segmented into type, treatment, and region. On the basis of the type the market is further bifurcated into Hemophilia A, Hemophilia B, and Hemophilia C. The market based on treatment is segmented into replacement therapy, ITI therapy, and gene therapy. Based on the geography the market is further segregated into North America, Latin America, Middle East & Africa, Europe and Asia Pacific.
Hemophilia Market Competitive Landscape
The players associated with the global Hemophilia Market include Biogen, Chagui Pharmaceutical, Novo Nordisk, Bayer Healthcare, Shire Plc, CSL Behring, Pfizer, Baxalta, and Octapharma.

Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
Chapter 4. Market Outlook
4.1. Market Dynamics
4.1.1. Market Drivers
4.1.2. Market Restraints
4.1.3. Market Opportunities
4.2. Porter’s Analysis
4.3. Value Chain Analysis
Chapter 5. Hemophilia Market, By Type
5.1. Hemophilia Market, by Type, 2018-2026
5.2. Hepatitis A
5.3 Hepatitis B
5.4 Hepatitis C
5.5 Others
Chapter 6. Hemophilia Market, By Treatment
6.1. Hemophilia Market, by Treatment, 2018-2026
6.2. Replacement Therapy
6.3 ITI Therapy
6.4 Gene Therapy
Chapter 7. Hemophilia Market, By Regions
7.1. Hemophilia Market, by Region, 2018-2026
7.1.1. North America
7.1.1.1. U.S
7.1.1.2. Rest of North America
7.1.2. Europe
7.1.2.1. U.K.
7.1.2.2. Germany
7.1.2.3. France
7.1.2.4. Rest of the Europe
7.1.3. Middle East & Africa (MEA)
7.1.3.1. GCC
7.1.3.2. North Africa
7.1.3.3. South Africa
7.1.3.4. Rest of MEA
7.1.4. Latin America (LATAM)
7.1.4.1. Brazil
7.1.4.2. Rest of LATAM
7.1.5. Asia Pacific (APAC)
7.1.5.1. India
7.1.5.2. China
7.1.5.3. Japan
7.1.5.4. Rest of the APAC
Chapter 8. Competitive Landscape
8.1.1. Key Strategies Adopted by Players
8.1.2. Market Share/Positioning Analysis
Chapter 9. Company Profiles
9.1. Pfizer, Inc.
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Novo Nordisk
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Baxalta
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Biogen
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Shire Plc
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Chugai Pharmaceutical
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Bayer Healthcare
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. CSL Behring
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. Octapharma
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
Chapter 10. Appendix
10.1. About Us
10.2. Glossary of Terms
Biogen
Chagui Pharmaceutical
Novo Nordisk
Bayer Healthcare
Shire Plc
CSL Behring
Pfizer
Baxalta
Octapharma

Select License Type
USD $4250
USD $6250
Connect With Us

+1-707-633-0404